Delta-10 THC

Δ¹⁰-THC is a minor positional isomer with the double bond between C10 and C10a. It is present in cannabis only at trace levels and reaches the market almost exclusively via semi-synthesis from CBD or Δ⁹-THC using Lewis-acid catalysts. Peer-reviewed pharmacology is sparse; the compound is presumed to be a weaker CB1 partial agonist than Δ⁹-THC based on structure–activity analogies, but no published human controlled trials characterize its subjective effects, pharmacokinetics, or safety. Commercial Δ¹⁰ mixtures typically contain a blend of 6a,10a-trans and -cis stereoisomers plus residual CBD, olivetol, and undisclosed reaction byproducts. Because no natural-source pathway produces meaningful Δ¹⁰ concentrations, regulators in several jurisdictions treat it as a synthetic compound outside the scope of hemp-derived exemptions. Evidence level: in vitro analogy only; no human RCT data. → See also: Delta-8 THC, Synthetic cannabinoid.